Cargando…
Anti-Diabetic Activity of Glycyrrhetinic Acid Derivatives FC-114 and FC-122: Scale-Up, In Silico, In Vitro, and In Vivo Studies
Type 2 diabetes (T2D) is one of the most common diseases and the 8th leading cause of death worldwide. Individuals with T2D are at risk for several health complications that reduce their life expectancy and quality of life. Although several drugs for treating T2D are currently available, many of the...
Autores principales: | Álvarez-Almazán, Samuel, Solís-Domínguez, Luz Cassandra, Duperou-Luna, Paulina, Fuerte-Gómez, Teresa, González-Andrade, Martin, Aranda-Barradas, María E., Palacios-Espinosa, Juan Francisco, Pérez-Villanueva, Jaime, Matadamas-Martínez, Félix, Miranda-Castro, Susana Patricia, Mercado-Márquez, Crisóforo, Cortés-Benítez, Francisco |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10454726/ https://www.ncbi.nlm.nih.gov/pubmed/37628991 http://dx.doi.org/10.3390/ijms241612812 |
Ejemplares similares
-
Indole- and Pyrazole-Glycyrrhetinic Acid Derivatives as PTP1B Inhibitors: Synthesis, In Vitro and In Silico Studies
por: De-la-Cruz-Martínez, Ledy, et al.
Publicado: (2021) -
The Neonatal Fc Receptor (FcRn): A Misnomer?
por: Pyzik, Michal, et al.
Publicado: (2019) -
The neonatal Fc receptor in cancer FcRn in cancer
por: Cadena Castaneda, Diana, et al.
Publicado: (2020) -
The influence of antibody engineering on Fc conformation and Fc receptor binding properties: Analysis of FcRn-binding engineered antibodies and an Fc fusion protein
por: Suzuki, Takuo, et al.
Publicado: (2021) -
FC centenary
Publicado: (1969)